Benzinga | Oct 26, 2020 07:18AM EDT

SVB Leerink Maintains Outperform on Mirati Therapeutics, Raises Price Target to $195

SVB Leerink analyst Andrew Berens maintains Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and raises the price target from $134 to $195.